PSFG
CPRX

Park Square Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Park Square Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-98
Closed -$2.13K – 399
2025
Q2 		$2.13K Buy
+98
New +$2.31K ﹤0.01% 884
2025
Q1 		– Sell
-1,379
Closed -$28.8K – 983
2024
Q4 		$28.8K Buy
+1,379
New +$29.6K 0.02% 359

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Park Square Financial Group's CPRX Position: Q3 2025 in Review

Park Square Financial Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 98 shares — an estimated $2.13K sold.

Park Square Financial Group first reported a position in CPRX in Q4 2024 and held it in 2 quarters. The position peaked at $28.8K in Q4 2024. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Park Square Financial Group reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 98 Catalyst Pharmaceutical shares in Q3 2025, an estimated $2.13K.
  • Park Square Financial Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 2 quarters.
  • Park Square Financial Group's Catalyst Pharmaceutical position peaked at $28.8K in Q4 2024.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.